ABSTRACT
BACKGROUND: Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. OBJECTIVE: To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. METHODS: Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL. RESULTS: Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. LIMITATIONS: Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. CONCLUSION: Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.
Subject(s)
Acquired Immunodeficiency Syndrome , HIV Infections , Herpesvirus 8, Human , Sarcoma, Kaposi , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Retrospective Studies , Sarcoma, Kaposi/epidemiologyABSTRACT
BACKGROUND: HIV pre-exposure prophylaxis (PrEP) was implemented in France in November 2015 based on individual-level risk factors for HIV infection. We evaluated the proportion of missed opportunities for PrEP among newly HIV-diagnosed people entering the Dat'AIDS cohort in 2016. METHODS: Multicenter retrospective analysis in 15 French HIV clinical centers of patients with a new diagnosis of HIV infection. Among them we differentiated patients according to the estimated date of infection: those occurring in the PrEP area (a previous negative HIV test in the last 12 months or those with an incomplete HIV-1 western blot (WB) with no HIV-1 anti-Pol-antibody at time of HIV diagnosis) and those in the pre-PrEP area (older infections). Epidemiological, biological and clinical data at HIV diagnosis were collected. Clinicians retrospectively identified potential eligibility for PrEP based on individual-level risk factors for HIV infection among those infected in the PrEP area. RESULTS: Among 966 patients with a new HIV diagnosis, 225 (23.3%) were infected in the PrEP area and 121 (53.8%) had complete data allowing evaluation of PrEP eligibility. Among them, 110 (91%) would have been eligible for PrEP, median age 31 years, with 68 (75.6%) born in France and 10 (11.1%) in Central/West Africa, with more than one previous STI in 19 (15.7%). The main eligibility criteria for PrEP were being a man who had sex with men or transgender 91 (82.7%) with at least one of the following criteria: unprotected anal sex with ≥2 partners in the last 6 months: 67 (60.9%); bacterial sexually transmitted infection in the last 12 months: 33 (30%); Use of psychoactive substances in a sexual context (chemsex): 16 (14.5%). PrEP was indicated for other HIV risk factors in 25 (22.7%). CONCLUSION: With 91% (110/121) of patients infected in the PrEP area eligible for PrEP, this study highlights the high potential of PrEP in avoiding new infection in France but also shows a persistent delay in HIV testing. Thus, an important limit on PrEP implementation in France could be insufficient screening and care access.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/prevention & control , Pre-Exposure Prophylaxis , AIDS Serodiagnosis , Adult , Africa, Western , Cohort Studies , Delayed Diagnosis , Female , France , HIV-1 , Homosexuality, Male , Humans , Male , Middle Aged , Retrospective Studies , Sexual Behavior , Sexual Partners , Transgender Persons , Unsafe SexABSTRACT
OBJECTIVE: To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients' characteristics related to the use of protease inhibitors in 2015. METHODS: We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients' characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015. RESULTS: We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load Ë5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count Ë200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age. CONCLUSION: The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women.
Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Practice Patterns, Physicians' , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/statistics & numerical data , Cohort Studies , Drug Therapy, Combination , Female , France/epidemiology , HIV , HIV Infections/epidemiology , HIV Protease Inhibitors/therapeutic use , History, 21st Century , Humans , Male , Middle Aged , Practice Patterns, Physicians'/history , Practice Patterns, Physicians'/statistics & numerical data , Practice Patterns, Physicians'/trends , Reverse Transcriptase Inhibitors/therapeutic use , Viral LoadABSTRACT
OBJECTIVES: The aim of the study was to determine whether there is a relationship between social deprivation and time of HIV diagnosis in France. METHODS: Prospectively collected data from a multicentre database were used in the study. Patients with a first HIV diagnosis between 1 January 2014 and 31 December 2015 were selected from the database. Deprivation was measured using the European Deprivation Index (EDI), which is an ecological index constructed from the address of residence and based on the smallest geographical census unit, in which individuals are classified so as to be comparable with national quintiles. Time of diagnosis was classified as being at an early, intermediate, late, or advanced stage of disease. Age, gender, distance from home to HIV centre, most probable route of infection, and hepatitis B or C coinfection were considered in the analysis. Because of a strong interaction between gender and most probable route of infection, we constructed a 'population' variable: men who have sex with men (MSM), heterosexual men and women. RESULTS: Of 1421 newly diagnosed patients, 44% were diagnosed either late or at an advanced stage of disease, and 46.3% were in the highest deprivation quintile. Using multivariate logistic regression, 'population' [odds ratio (OR) 0.62 (95% confidence interval (CI) 0.48-0.78) for MSM compared with women] and age [OR 1.39 (95% CI 1.07-1.80), 1.72 (1.32-2.23) and 1.86 (1.40-2.47) for the second, third and fourth quartiles, respectively, compared with the first quartile] were found to be related to late diagnosis. EDI level was not related to late HIV diagnosis. CONCLUSIONS: 'Population' seems to be more relevant than EDI to define evidence-based interventions to limit late diagnosis.
Subject(s)
Delayed Diagnosis/statistics & numerical data , HIV Infections/diagnosis , Heterosexuality/statistics & numerical data , Homosexuality, Male/statistics & numerical data , Adult , Female , France , HIV Infections/psychology , Health Status Disparities , Humans , Logistic Models , Male , Middle Aged , Prospective Studies , Risk Factors , Socioeconomic FactorsABSTRACT
OBJECTIVES: The aim of this study was to describe the proportion of liver-related diseases (LRDs) as a cause of death in HIV-infected patients in France and to compare the results with data from our five previous surveys. METHODS: In 2010, 24 clinical wards prospectively recorded all deaths occurring in around 26 000 HIV-infected patients who were regularly followed up. Results were compared with those of previous cross-sectional surveys conducted since 1995 using the same design. RESULTS: Among 230 reported deaths, 46 (20%) were related to AIDS and 30 (13%) to chronic liver diseases. Eighty per cent of patients who died from LRDs had chronic hepatitis C, 16.7% of them being coinfected with hepatitis B virus (HBV). Among patients who died from an LRD, excessive alcohol consumption was reported in 41%. At death, 80% of patients had undetectable HIV viral load and the median CD4 cell count was 349 cells/µL. The proportion of deaths and the mortality rate attributable to LRDs significantly increased between 1995 and 2005 from 1.5% to 16.7% and from 1.2 to 2.0, respectively, whereas they tended to decrease in 2010 to 13% and 1.1, respectively. Among liver-related causes of death, the proportion represented by hepatocellular carcinoma (HCC) dramatically increased from 5% in 1995 to 40% in 2010 (p = 0.019). CONCLUSIONS: The proportion of LRDs among causes of death in HIV-infected patients seems recently to have reached a plateau after a rapid increase during the decade 1995-2005. LRDs remain a leading cause of death in this population, mainly as a result of hepatitis C virus (HCV) coinfection, HCC representing almost half of liver-related causes of death.
Subject(s)
Alcohol Drinking/mortality , Carcinoma, Hepatocellular/mortality , HIV Infections/mortality , Hepatitis C, Chronic/mortality , Liver Cirrhosis, Alcoholic/mortality , Liver Neoplasms/mortality , Adult , CD4 Lymphocyte Count , Carcinoma, Hepatocellular/immunology , Cause of Death/trends , Cross-Sectional Studies , Female , France/epidemiology , HIV Infections/complications , HIV Infections/immunology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/immunology , Humans , Liver Cirrhosis, Alcoholic/complications , Liver Cirrhosis, Alcoholic/immunology , Liver Neoplasms/immunology , Male , Middle Aged , Prospective StudiesABSTRACT
INTRODUCTION: The yellow-fever vaccination center of the Tourcoing Hospital (France) has been accessible to Belgian travelers since its opening in 1994. METHOD: The authors reported the specificities of these consultations during the year 2010, by retrospectively analyzing electronic medical records. RESULTS: Some medical issues encountered during the consultation were due to differences in vaccination schedules: for the polio vaccine, since the last dose is administered between 5 and 7 years of age in Belgium; and for the measles vaccine since a late two-dose schedule (second dose between 12 and 13 years of age) is recommended in this country. Moreover, some specific vaccines are available only in Belgium: a diphtheria-tetanus bivalent vaccine, and a live attenuated oral typhoid vaccine. DISCUSSION: The specificities of the Belgian border traveler consultation in our French yellow-fever center are due to a difference in European vaccination schedules; the physician must be aware of these. CONCLUSION: The physician has to propose updates on vaccination schedules, and be aware of yellow-fever vaccine compatibility with vaccines recently administered in Belgium.
Subject(s)
Immunization Schedule , Travel , Vaccination/statistics & numerical data , Adolescent , Adult , Age Factors , BCG Vaccine , Belgium , Child , Child, Preschool , Diphtheria-Tetanus-Pertussis Vaccine , Emigration and Immigration , Female , France , Health Policy , Humans , Immunization, Secondary , Infant , Male , Middle Aged , Practice Guidelines as Topic , Retrospective Studies , Viral Vaccines , Young AdultSubject(s)
AIDS-Related Opportunistic Infections/complications , Abscess/etiology , HIV-1 , Immune Reconstitution Inflammatory Syndrome/etiology , Lymphadenitis/etiology , Mycobacterium avium-intracellulare Infection/complications , Abscess/surgery , Adult , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Antitubercular Agents/therapeutic use , Axilla , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Darunavir , Dideoxynucleosides/administration & dosage , Dideoxynucleosides/therapeutic use , Enfuvirtide , Ethambutol/administration & dosage , Ethambutol/therapeutic use , HIV Envelope Protein gp41/administration & dosage , HIV Envelope Protein gp41/therapeutic use , Humans , Isoniazid/administration & dosage , Isoniazid/therapeutic use , Lamivudine/administration & dosage , Lamivudine/therapeutic use , Lymph Node Excision , Lymphadenitis/surgery , Male , Mycobacterium avium-intracellulare Infection/surgery , Peptide Fragments/administration & dosage , Peptide Fragments/therapeutic use , Pyrazinamide/administration & dosage , Pyrazinamide/therapeutic use , Rifampin/administration & dosage , Rifampin/therapeutic use , Ritonavir/administration & dosage , Ritonavir/therapeutic use , Streptomycin/administration & dosage , Streptomycin/therapeutic use , Sulfonamides/administration & dosage , Sulfonamides/therapeutic useABSTRACT
A case of Salmonella paratyphi A infection was diagnosed late in a patient treated for febrile pneumonia after his returning from India. This case was remarkable in two aspects: first, it illustrated the reemergence of S.paratyphi A infections in people having traveled to India, with increasing fluoroquinolone resistance, and second the difficulty of diagnosing this disease, since the patient was initially treated for pneumonia and flu-like syndrome. Salmonella typhi or paratyphi infections should be evoked in case of persistent fever in patients having traveled to endemic areas, even if digestive signs are absent. Furthermore, choosing an empiric antibiotic treatment with fluoroquinolones could lead to treatment failure if the patient traveled in a country where fluoroquinolone resistance is high, as in Asia and especially in India.